Erratum: Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients (Leukemia (2013) 27 (213-219) DOI: 10.1038/leu.2012.197);Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients

Leukemia

Volumn 27, Issue 1, 2013, Pages 213-219

  Ludwig, H ^a   Milosavljevic, D ^a   Zojer, N ^a   Faint, J M ^b   Bradwell, A R ^c   Hubl W ^a   Harding, S J ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b Binding Site Group Ltd   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

heavy light chain assay; monoclonal immunoglobulin; multiple myeloma; response evaluation and prognostication

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; M PROTEIN; PARAPROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; ELECTROPHORESIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NEPHELOMETRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN ELECTROPHORESIS; RISK FACTOR;

EID: 84873566056     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.25     Document Type: Erratum

References (34)

1. Harousseau JL, Attal M, Avet-Loiseau H, Margit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-4629.
2. Paiva B, Almeida J, Pé rez-André s M, Mateo G, López A, Rasillo A et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010; 78: 239-252.
3. Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol 1986; 13: 282-290.
4. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV. San Miguel J, Chanan-Khan A et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701-4705.
5. Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electropheresis and immunonephelometry. Clin Chem 2009; 55: 1523-1529.
6. Riches PG, Sheldon J, Smith AM, Hobbs JR. Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem 1991; 28: 253-259.
7. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009; 55: 1646-1655.
8. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment in multiple myeloma. Leukemia 2009; 23: 3-9.
9. Seetharam A, Mirbahai L, Lovatt T, Macwhannell A, Jacob A, Handa S et al. Heavy/light chain ratios provide a rapid and sensitive alternative to IFE in identifying haematological malignancies. 13th International Myeloma Workshop, Paris 2011. Haematologica 2011; 96: P 80.
10. Avet-Loiseau H, Young P, Mathiot C, Attal M, Moreau P, Harousseau J et al. Multiple myeloma outcome is associated with polyclonal immunoglobulin suppression of the same isotype as the tumour. Haematologica 2011; 96: 382.
11. Wechalekar A, Faint J, Bradwell S, Lachmann H, Hawkings P, Harding S et al. Significance of abnormal serum immunoglobulin heavy/light chain ratios (Hevylite) in 294 patients with systemic AL amyloidosis. Haematologica 2011; 96: 392.
12. Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S et al. Novel M-component based biomarkers in Waldenströ m's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11: 164-167.
13. Katzmann JA, Clark R, Dispenzieri A, Kyle R, Landgren O, Bradwell A et al. Isotypespecific heavy/light chain (HLC) suppression as a predictor of myeloma development in monoclonal gammopathy of undetermined significance (MGUS). Blood (ASH Annual Meeting Abstracts) 2009; 114: 1788.
14. Donato LJ, Zeldenrust SR, Murray DL, Katzmann JA. A-71-year-old woman with multiple myeloma status after stem cell transplantation. Clin Chem 2011; 57: 1645-1648.
15. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
16. Bladé J, Samson D, Reece D, Apperley J, Bjö rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
17. Kaur A, Snelus T, Mitchell F, Showell PJ, Drayson MT, Bradwell AR et al. Turbidimetric immunoassays for IgAk and IgAl quantification for the assessment of patients with multiple myeloma. Clin Chem 2010; 56: B 170a.
18. Alvi AJ, Fourrier NJ, Shemar M, Bradwell AR, Harding SJ. Turbidimetric immunoassays for IgGk and IgGl quantification for the assessment of patients with IgG multiple myeloma. Clin Chem 2011; 57: A 26a.
19. Reed 3rd JF, Stark DB. Robust alternatives to traditional analysis of variance: Welch W, James J I, James J II, Brown-Forsythe BF. Comput Methods Programs Biomed 1988; 26: 233-237.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn 1958; 53: 457-481.
21. Cox D. Regression models and life tables. J Royal Stat Soc 1972; 34: 187-220.
22. Wang H, Gao C, Xu L, Yang Z, Hao W, Kong X. Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China. Cell Mol Immunol 2008; 5: 293-298.
23. Avet-Loiseau H, Mirbahai L, Harousseau JL, Moreau P, Mathiot C, Facon T et al. Serum immunoglobulin heavy/light chain ratios are independent risk factors for predicting progression free survival in multiple myeloma. Haematologica 2010; 95(395): 0953.
24. Chandy KG, Stockley RA, Leonard RC, Crockson RA, Burnett D, MacLennan IC. Relationship between serum viscosity and intravascular lgA polymer concentrations in lgA myeloma. Clin Exp Immunol 1981; 46: 653-661.
25. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1-110.
26. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
27. Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011; 29: 1627-1633.
28. Hari P, Pasquini MC, Logan BR, Stadmauer EA, Krishnan A, Howard A et al. Immunglobulin free light chain (FLC) and heavy chain/light chain (HLC) assays-comparison with electrophoretic responses in multiple myeloma (MM). Blood 2011; 118: 2877.
29. Fernández de Larrea C, Tovar N, Cibeira MT, Aró stegui JI, Rosiñ ol L, Elena M et al. Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Heamatologica 2011; 96: 171-173.
30. Leibson PJ, Loken MR, Panem S, Schreiber H. Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression. Proc Natl Acad Sci USA 1979; 76: 2937-2941.
31. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22: 1933-1937.
32. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Heamatol 2007; 137: 240-243.
33. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
34. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 4908-4915.